As a trusted clinical research organization (CRO) with an on site phase 1 clinical pharmacology unit for human abuse potential (HAP) trials, Dr. Vince Clinical Research is relied upon by sponsors to conduct these trials with a high degree of precision and accuracy. Our team brings deep regulatory insight through proactive collaboration with the Food and Drug Administration (FDA) and extensive experience across a wide range of drug types. This combination makes DVCR well-equipped to design and execute these complex studies confidently.
‘Regulatory Considerations’ is part 8 and concludes our Human Abuse Potential video series. Join Dr. Lynn Webster, Executive Vice President of Scientific Affairs at Dr. Vince Clinical Research, as he discusses when and why a Human Abuse Potential Study may be required during drug development, how these studies vary based on drug type and what initiates multiple trials to be needed. Visit our channel to watch our complete HAP series playlist, where we continue to showcase what makes DVCR experts in human abuse potential studies.
